Oruka Therapeutics, Inc. — Form 8-K
Filed October 26, 2026 · analyzed by the 8-K Agent
8-K
▲ Likely positive
significance 72/100
What the filing says
Oruka announced positive Week 16 interim results from EVERLAST-B, a 187-patient Phase 2b trial of ORKA-001 (IL-23p19 monoclonal antibody) in moderate-to-severe psoriasis. The high-dose group (600 mg at Weeks 0 and 4) achieved 61% PASI 100 and 86% PASI 90 versus 0% placebo (p<0.0001), with safety comparable to placebo (39% vs 43% any adverse events). Company plans Phase 3 initiation in 1H 2027 and reports >$1B cash runway through BLA filing.
Why this rating
Confirmatory Phase 2b efficacy aligns with Phase 2a, supporting Phase 3 advancement in major market ($11B psoriasis category). Relative to $371.5M market cap, successful Phase 3 initiation is material but de-risks pivotal stage; still clinical-stage risk remains high.
Price action (we called it positive)
before filing · preread $78.55 | at our read pending | +10 min pending | +30 min pending | +1 hr pending | +4 hrs pending |
Quotes via Yahoo Finance at capture time; for filings arriving outside market hours the clock starts at the next open. Not investment advice. How accurate are our calls? →
See more from October 26, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.